PL3142750T3 - Kompozycje zawierające aav eksprymujące konstrukty podwójnych przeciwciał i ich zastosowania - Google Patents

Kompozycje zawierające aav eksprymujące konstrukty podwójnych przeciwciał i ich zastosowania

Info

Publication number
PL3142750T3
PL3142750T3 PL15792528T PL15792528T PL3142750T3 PL 3142750 T3 PL3142750 T3 PL 3142750T3 PL 15792528 T PL15792528 T PL 15792528T PL 15792528 T PL15792528 T PL 15792528T PL 3142750 T3 PL3142750 T3 PL 3142750T3
Authority
PL
Poland
Prior art keywords
applications
compositions containing
double antibody
containing aav
aav expressing
Prior art date
Application number
PL15792528T
Other languages
English (en)
Inventor
James M. Wilson
Anna Tretiakova
Original Assignee
The Trustees Of The University Of Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54480597&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3142750(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Trustees Of The University Of Pennsylvania filed Critical The Trustees Of The University Of Pennsylvania
Publication of PL3142750T3 publication Critical patent/PL3142750T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
    • C12N2830/205—Vector systems having a special element relevant for transcription transcription of more than one cistron bidirectional
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
PL15792528T 2014-05-13 2015-05-13 Kompozycje zawierające aav eksprymujące konstrukty podwójnych przeciwciał i ich zastosowania PL3142750T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461992649P 2014-05-13 2014-05-13
PCT/US2015/030533 WO2015175639A1 (en) 2014-05-13 2015-05-13 Compositions comprising aav expressing dual antibody constructs and uses thereof
EP15792528.0A EP3142750B1 (en) 2014-05-13 2015-05-13 Compositions comprising aav expressing dual antibody constructs and uses thereof

Publications (1)

Publication Number Publication Date
PL3142750T3 true PL3142750T3 (pl) 2021-03-08

Family

ID=54480597

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15792528T PL3142750T3 (pl) 2014-05-13 2015-05-13 Kompozycje zawierające aav eksprymujące konstrukty podwójnych przeciwciał i ich zastosowania

Country Status (27)

Country Link
US (4) US10138295B2 (pl)
EP (1) EP3142750B1 (pl)
JP (3) JP6974943B2 (pl)
KR (1) KR102550926B1 (pl)
CN (1) CN106470736B (pl)
AU (2) AU2015259188B2 (pl)
CA (1) CA2947614C (pl)
CL (1) CL2016002840A1 (pl)
CR (1) CR20160519A (pl)
DK (1) DK3142750T3 (pl)
EA (1) EA037980B1 (pl)
ES (1) ES2833230T3 (pl)
HR (1) HRP20201530T1 (pl)
HU (1) HUE050609T2 (pl)
IL (1) IL248508B2 (pl)
MA (2) MA44179B1 (pl)
MX (1) MX365658B (pl)
MY (1) MY186389A (pl)
PE (1) PE20170261A1 (pl)
PH (1) PH12016502239B1 (pl)
PL (1) PL3142750T3 (pl)
PT (1) PT3142750T (pl)
SA (1) SA516380285B1 (pl)
SG (1) SG11201609207SA (pl)
SI (1) SI3142750T1 (pl)
UA (1) UA123986C2 (pl)
WO (1) WO2015175639A1 (pl)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9719106B2 (en) 2013-04-29 2017-08-01 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
CR20160519A (es) 2014-05-13 2017-01-27 The Trustees Of The Univ Of Pennysylvania Composiciones que comprenden avv que expresa constructos de anticuerpos duales y sus usos
WO2016200543A2 (en) 2015-05-13 2016-12-15 The Trustees Of The University Of Pennsylvania Aav-mediated expression of anti-inluenza antibodies and methods of use thereof
US11174495B2 (en) 2015-12-04 2021-11-16 Board Of Regents, The University Of Texas System Reporter system for detecting and targeting activated cells
EP4085934A1 (en) * 2015-12-11 2022-11-09 The Trustees of The University of Pennsylvania Gene therapy for treating familial hypercholesterolemia
CA3015347A1 (en) 2016-02-24 2017-08-31 Visterra, Inc. Formulations of antibody molecules to influenza virus
IL262207B2 (en) * 2016-04-15 2026-01-01 Univ Pennsylvania Preparations for the treatment of wet age-related macular degeneration
JP2019515027A (ja) * 2016-04-15 2019-06-06 レジェンクスバイオ インコーポレーテッド 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療
WO2017184463A1 (en) * 2016-04-17 2017-10-26 The Trustees Of The University Of Pennsylvania Compositions and methods useful for prophylaxis of organophosphates
WO2017189963A1 (en) * 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3448987A4 (en) * 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
EP3448874A4 (en) * 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
BR112018072865A2 (pt) * 2016-05-12 2019-04-30 Janssen Vaccines & Prevention B.V. promotor bidirecional potente e equilibrado
US11001858B2 (en) * 2016-06-20 2021-05-11 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
CA3034089A1 (en) 2016-08-18 2018-02-22 The Regents Of The University Of California Crispr-cas genome engineering via a modular aav delivery system
RS65241B1 (sr) 2017-02-28 2024-03-29 Univ Pennsylvania Vektor adeno-asociranih virusa (aav) iz podgrupe f i njegove upotrebe
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
TW201837170A (zh) 2017-02-28 2018-10-16 賓州大學委員會 新穎ａａｖ媒介的流感疫苗
MX2020001593A (es) 2017-08-09 2020-07-13 Bioverativ Therapeutics Inc Moleculas de acido nucleico y usos de las mismas.
CA3073161A1 (en) * 2017-08-17 2019-02-21 The Trustees Of The University Of Pennsylvania Modified mrna vaccines encoding herpes simplex virus glycoproteins and uses thereof
CA3086045A1 (en) 2017-12-19 2019-06-27 Akouos, Inc. Aav-mediated delivery of therapeutic antibodies to the inner ear
US12558434B2 (en) 2018-02-20 2026-02-24 The Trustees Of The University Of Pennsylvania Compositions for treatment of wet age-related macular degeneration
CN108424934A (zh) * 2018-04-16 2018-08-21 和元生物技术（上海）股份有限公司 一种慢病毒cag-cmv双启动子改造载体构建及应用
CA3106078A1 (en) 2018-07-17 2020-01-23 Junghun Lee Treatment of neuropathy with dna constructs expressing igf-1 isoforms
JP7602454B2 (ja) 2018-08-09 2024-12-18 バイオベラティブ セラピューティクス インコーポレイテッド 核酸分子及び非ウイルス遺伝子治療のためのそれらの使用
US20200148762A1 (en) * 2018-11-09 2020-05-14 Avamab Pharma Inc. Methods for regulating endogenous production of antibodies against infectious diseases
EP3886898A4 (en) 2018-12-01 2022-08-24 International AIDS Vaccine Initiative RECOMBINANT HIV ENV POLYPEPTIDES AND THEIR USE
WO2020132382A1 (en) * 2018-12-21 2020-06-25 Merck Sharp & Dohme Corp. Expression vectors for eukaryotic expression systems
CN119390787A (zh) 2019-01-31 2025-02-07 俄勒冈健康与科学大学 用于aav衣壳的使用转录依赖性定向进化的方法
US20220195462A1 (en) * 2019-04-24 2022-06-23 Regenxbio Inc. Fully-human post-translationally modified antibody therapeutics
CN115175931A (zh) * 2019-09-17 2022-10-11 奥本大学 用于治疗和预防狂犬病病毒属感染的抗体基因疗法
MX2022007207A (es) * 2019-12-11 2022-07-12 Visterra Inc Composiciones y metodos para tratar y prevenir la influenza.
WO2022107090A1 (en) * 2020-11-23 2022-05-27 Novartis Ag Expression technology for antibody constructs
IL303317A (en) 2020-12-01 2023-07-01 Akouos Inc ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA
MX2023008826A (es) 2021-02-01 2023-09-15 Regenxbio Inc Terapia génica para lipofuscinosis neuronal ceroidea.
WO2022169884A2 (en) * 2021-02-02 2022-08-11 Allen Institute Artificial expression constructs for modulating gene expression in gabaergic neurons and astrocytes
CN118186005A (zh) * 2022-12-12 2024-06-14 苏州荷光科汇生物科技有限公司 一种适于阿达木单抗的表达盒及其载体与应用
CN117777279B (zh) * 2023-06-13 2025-02-14 康元医疗科技(大连)有限公司 一种纳米抗体、包含该纳米抗体的多肽及其应用
WO2026064462A1 (en) * 2024-09-18 2026-03-26 Genzyme Corporation Production of recombinant aav

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US6268213B1 (en) 1992-06-03 2001-07-31 Richard Jude Samulski Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy
US5869305A (en) 1992-12-04 1999-02-09 The University Of Pittsburgh Recombinant viral vector system
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US5741683A (en) 1995-06-07 1998-04-21 The Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
EP1007637B1 (en) 1997-04-14 2004-06-30 Cell Genesys, Inc. Methods for increasing the efficiency of recombinant aav product
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
US5891994A (en) 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
GB9720585D0 (en) 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
HUP9900956A2 (hu) * 1998-04-09 2002-04-29 Aventis Pharma Deutschland Gmbh. Egyláncú, több antigéntkötőhely kialakítására képes molekulák, előállításuk és alkalmazásuk
US6146874A (en) 1998-05-27 2000-11-14 University Of Florida Method of preparing recombinant adeno-associated virus compositions
EP1135468B1 (en) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
US6596535B1 (en) 1999-08-09 2003-07-22 Targeted Genetics Corporation Metabolically activated recombinant viral vectors and methods for the preparation and use
US6780639B1 (en) * 1999-08-24 2004-08-24 Universite Libre De Bruxelles Antibiotic inducible/repressible genetic construct for gene therapy or gene immunization
JP2003529559A (ja) 2000-01-31 2003-10-07 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規用途
AU6814901A (en) 2000-06-01 2001-12-11 Univ North Carolina Methods and compounds for controlled release of recombinant parvovirus vectors
US7465583B2 (en) 2000-06-01 2008-12-16 The University Of North Carolina At Chapel Hill Duplexed parvovirus vectors
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
DK2359869T3 (en) 2001-12-17 2019-04-15 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
AU2003274397A1 (en) 2002-06-05 2003-12-22 University Of Florida Production of pseudotyped recombinant aav virions
NZ537277A (en) * 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
US8337841B2 (en) 2003-01-21 2012-12-25 Chugai Seiyaku Kabushiki Kaisha Methods of screening for antibody light chains
US8005620B2 (en) 2003-08-01 2011-08-23 Dna Twopointo Inc. Systems and methods for biopolymer engineering
WO2005012877A2 (en) 2003-08-01 2005-02-10 Dna Twopointo Inc. Systems and methods for antibody engineering
EP1668143B1 (en) 2003-09-30 2013-03-20 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
US20060246079A1 (en) 2003-11-14 2006-11-02 Morrow Phillip R Neutralizing human antibodies to anthrax toxin
CN1981039A (zh) * 2004-05-10 2007-06-13 巴斯福植物科学有限公司 组装多表达构建体的方法
EP1765846A4 (en) 2004-07-13 2010-02-17 Cell Genesys Inc AAV VECTOR COMPOSITIONS AND ITS USE IN PROCESSES FOR INCREASING IMMUNOGLOBULIN EXPRESSION
DE23193606T1 (de) 2005-04-07 2024-02-15 The Trustees Of The University Of Pennsylvania Verfahren zur erhöhung der funktion eines aav-vektors
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
US20070292922A1 (en) 2006-03-31 2007-12-20 Cell Genesys, Inc. Regulated expression of recombinant proteins from adeno-associated viral vectors
CN101528916B (zh) 2006-04-28 2013-09-04 宾夕法尼亚大学托管会 规模可调的aav生产方法
JP5675109B2 (ja) 2007-02-20 2015-02-25 アナプティスバイオ インコーポレイティッド ライブラリーの生成方法及びその使用
WO2008124934A1 (en) 2007-04-17 2008-10-23 National Research Council Of Canada Constructs for enhancement of gene expression in muscle
US7879326B2 (en) 2007-06-15 2011-02-01 The Board Of Trustees Of The Leland Stanford Junior University Human neutralizing monoclonal antibodies to H5N1 influenza A virus
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
WO2010002862A2 (en) 2008-07-01 2010-01-07 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (fgfr3) binding proteins
CA2731686C (en) 2008-07-25 2020-04-07 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
CN104262483A (zh) 2009-01-26 2015-01-07 根马布股份公司 用于生成抗体混合物的方法
ES2549769T3 (es) 2009-03-25 2015-11-02 Genentech, Inc. Anticuerpos anti-FGFR3 y métodos que emplean los mismos
WO2010119991A2 (en) 2009-04-17 2010-10-21 Takeda Pharmaceutical Company Limited Novel method of treating cancer
KR101790354B1 (ko) 2009-05-11 2017-10-25 얀센 백신스 앤드 프리벤션 비.브이. 인플루엔자 바이러스 ｈ3ｎ2를 중화시킬 수 있는 인간 결합 분자 및 그것의 용도
IT1395961B1 (it) 2009-06-01 2012-11-02 Pomona Biotechnologies Llc Anticorpi monoclonali come medicamento per il trattamento terapeutico e/o profilattico delle infezioni da virus influenzale a (h1n1) di origine suina (s-oiv)
JP5745511B2 (ja) * 2009-06-25 2015-07-08 メディミューン，エルエルシー ブタインフルエンザヘマグルチニン変異体
CN101649328A (zh) * 2009-09-09 2010-02-17 陕西师范大学 表达多个外源基因的Ad5 D24条件复制型腺病毒载体及其构建方法和应用
US8598331B2 (en) 2009-09-28 2013-12-03 The University Of British Columbia CLDN5 mini-promoters
SG183149A1 (en) * 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
WO2011126868A1 (en) 2010-03-30 2011-10-13 Battelle Memorial Institute Buffy coat separator float systems and methods
CA2800311A1 (en) 2010-05-11 2011-11-17 Aveo Pharmaceuticals, Inc. Anti-fgfr2 antibodies
NZ603581A (en) 2010-06-19 2015-05-29 Sloan Kettering Inst Cancer Anti-gd2 antibodies
PE20171512A1 (es) 2010-08-13 2017-10-20 Roche Glycart Ag Anticuerpos anti-fap
WO2012023053A2 (en) * 2010-08-16 2012-02-23 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
JP6091435B2 (ja) * 2011-02-22 2017-03-08 カリフォルニア インスティチュート オブ テクノロジー アデノ随伴ウイルス（ａａｖ）ベクターを用いたタンパク質の送達
EP2500434A1 (en) 2011-03-12 2012-09-19 Association Institut de Myologie Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery
SG185832A1 (en) 2011-05-10 2012-12-28 Agency Science Tech & Res Fgfr1 antibodies and treatment of cancer
CA2828890A1 (en) 2011-04-07 2012-10-11 Genentech, Inc. Anti-fgfr4 antibodies and methods of use
EP3699286A1 (en) 2011-04-20 2020-08-26 The Trustees of the University of Pennsylvania Regimens and compositions for aav-mediated passive immunization of airborne pathogens
WO2012145759A2 (en) 2011-04-21 2012-10-26 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Methods of protein production and compositions thereof
CN103842601A (zh) 2011-09-29 2014-06-04 艾利丹尼森公司 增加营销机会的防盗安全装置
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
WO2013059206A2 (en) * 2011-10-17 2013-04-25 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Monospecific and bispecific human monoclonal antibodies targeting insulin-growth factor ii (igf-ii)
AR088941A1 (es) 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
WO2013155222A2 (en) 2012-04-10 2013-10-17 The Regents Of The University Of California Brain-specific enhancers for cell-based therapy
WO2013163427A1 (en) * 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibodies to treat hiv-1 infection
AR091116A1 (es) * 2012-05-22 2015-01-14 Bristol Myers Squibb Co Anticuerpos biespecificos y sus metodos de uso
EP4678239A3 (en) * 2012-08-01 2026-04-08 Ikaika Therapeutics, Inc. Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4)
US9719106B2 (en) 2013-04-29 2017-08-01 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
WO2015142661A1 (en) 2014-03-15 2015-09-24 Novartis Ag Regulatable chimeric antigen receptor
CR20160519A (es) 2014-05-13 2017-01-27 The Trustees Of The Univ Of Pennysylvania Composiciones que comprenden avv que expresa constructos de anticuerpos duales y sus usos

Also Published As

Publication number Publication date
US20190322725A1 (en) 2019-10-24
DK3142750T3 (da) 2020-09-14
IL248508B2 (en) 2023-02-01
BR112016026092A2 (pt) 2017-12-12
PH12016502239A1 (en) 2017-01-09
MY186389A (en) 2021-07-22
MX365658B (es) 2019-06-10
JP7229298B2 (ja) 2023-02-27
SI3142750T1 (sl) 2020-11-30
SA516380285B1 (ar) 2020-04-30
JP2021121217A (ja) 2021-08-26
US10975140B2 (en) 2021-04-13
US10385119B2 (en) 2019-08-20
EP3142750B1 (en) 2020-07-01
IL248508B (en) 2022-10-01
AU2021204630B2 (en) 2024-03-14
UA123986C2 (uk) 2021-07-07
JP2017515482A (ja) 2017-06-15
US20200216520A1 (en) 2020-07-09
MA39437A1 (fr) 2018-01-31
MX2016014813A (es) 2017-03-10
HUE050609T2 (hu) 2021-01-28
EA037980B1 (ru) 2021-06-18
KR20170002445A (ko) 2017-01-06
WO2015175639A1 (en) 2015-11-19
KR102550926B1 (ko) 2023-07-05
CR20160519A (es) 2017-01-27
US10138295B2 (en) 2018-11-27
EP3142750A4 (en) 2017-10-18
PE20170261A1 (es) 2017-04-12
US10647758B2 (en) 2020-05-12
JP2020141697A (ja) 2020-09-10
AU2021204630A1 (en) 2021-07-29
CL2016002840A1 (es) 2017-05-05
SG11201609207SA (en) 2016-12-29
MA44179A1 (fr) 2019-07-31
CN106470736B (zh) 2021-05-28
PH12016502239B1 (en) 2017-01-09
US20190031740A1 (en) 2019-01-31
AU2015259188A1 (en) 2016-11-10
PT3142750T (pt) 2020-09-22
CA2947614C (en) 2023-10-03
HRP20201530T1 (hr) 2020-12-11
US20170081392A1 (en) 2017-03-23
CN106470736A (zh) 2017-03-01
NZ725622A (en) 2023-10-27
CA2947614A1 (en) 2015-11-19
EP3142750A1 (en) 2017-03-22
EA201692293A1 (ru) 2017-04-28
ES2833230T3 (es) 2021-06-14
JP6974943B2 (ja) 2021-12-01
MA44179B1 (fr) 2020-10-28
AU2015259188B2 (en) 2021-07-29
IL248508A0 (en) 2016-12-29

Similar Documents

Publication Publication Date Title
PL3443009T3 (pl) Przeciwciała i kompozycje anty-tim-3
DK3368572T3 (da) Anti-pd-1-antistoffer og -sammensætninger
SI3142750T1 (sl) Sestavki, ki vsebujejo AAV izražen dvojni protitelesni konstrukt in uporaba le-tega
PL3148579T3 (pl) Przeciwciała anty-gitr i sposoby ich zastosowania
DK3310809T3 (da) Anti-cgrp-antistofformulering
PL3295951T3 (pl) Przeciwciała anty-pvrig i sposoby ich zastosowania
IL248519A0 (en) Bioceramic compositions and biomodulatory uses thereof
LT3556777T (lt) Daugiaspecifiniai antikūno konstruktai
PT3355990T (pt) Compostos semifluorados e as suas composições
DK3221363T3 (da) Antistoffer mod cd73 og anvendelser deraf
HUE045307T2 (hu) EGFRVIII-ellenes antitestek és alkalmazásaik
ME03558B (me) Molekuli anti-lag-3 antiтela i njihove upotrebe
EP3333331A4 (en) BUILDING STRUCTURE FOR MODULAR CONTAINERHAUS
HUE055357T2 (hu) Vegyületek kompozíciói és azok alkalmazásai
DK3484446T3 (da) Antistofsammensætninger
KR102068915B9 (ko) 조직 인자 경로 억제제 항체 및 그의 용도
DK3110447T3 (da) Anti-EGFR-antistof og anvendelser heraf
PT3261437T (pt) Compostos e composições fungicidas
PL3393485T3 (pl) Kompozycje probiotyczne i ich zastosowanie
PL3337506T3 (pl) Kombinacje i ich zastosowania
KR20180085008A (ko) 항-pcsk9 항체 및 그의 용도
IL264445A (en) Compounds and compositions and uses thereof
KR20180084930A (ko) 접착제 조성물 및 구조체
DK3193952T3 (da) Sammensætning indeholdende glycosaminoglycans og proteiner
PL3191080T3 (pl) Kompozycje pozajelitowe i ich zastosowanie